Clinical Trial: Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608718) titled 'Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer' on May 20.

Brief Summary: This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.

Study Start Date: Sept., 2026

Study Type: INTERV...